Novavax Management Set to Engage at Upcoming Jefferies London Healthcare Conference

Novavax Engages with Investors at Jefferies London Healthcare Conference

Novavax, Inc., renowned for its dedication to addressing significant health challenges globally through innovative vaccine technology, has announced its participation in the upcoming Jefferies London Healthcare Conference. This notable event is scheduled for November 17, 2026, where the company’s management will host a fireside chat starting at 5:00 PM GMT.

A Platform for Insights and Innovation

The Jefferies conference serves as a pivotal platform for investors to gain insights into Novavax’s ongoing developments, particularly in vaccine technology that leverages their proprietary Matrix-M® adjuvant and protein-based nanoparticles. These groundbreaking approaches empower the company to tackle pressing global health issues effectively.

The fireside chat will be live-streamed and accessible via the 'Events & Presentations' section of Novavax's Investor Relations website. Additionally, a replay of the session will be available for 30 days post-event, allowing broader audience access to the insights shared during the discussion.

About Novavax

Novavax, with its Nasdaq ticker NVAX, is committed to employing its scientific expertise and forward-thinking strategies to enhance public health through vaccines. The company's strategic growth framework is founded on three key pillars, prioritizing technology partnerships, capital-efficient research and development innovation, and maintaining a streamlined operation model. This approach includes maximizing the potential of marketed products such as Nuvaxovid™ and R21/Matrix-M™, along with focusing on research assets and collaborations that can amplify their impact in the healthcare sector.

As global health needs evolve, Novavax continues to explore new avenues for vaccine development and public health solutions. The company aims not only to advance its own pipeline but also to create solid partnerships that bolster its vaccination efforts against infectious diseases.

Conclusion

With the world facing an array of health challenges, Novavax positions itself at the forefront of vaccine innovation. By participating in events like the Jefferies London Healthcare Conference, Novavax fosters communication with investors and stakeholders, ensuring they understand the company’s vision and ongoing initiatives. This engagement underscores Novavax’s commitment to transparency and collaborative progress in the fight against infectious diseases.

For those interested in following Novavax's developments and updates, more information can be found on their official website and LinkedIn page. The company looks forward to sharing insights from the upcoming conference and continuing its mission to transform the landscape of vaccines and public health.